Related Experiment Video

Updated: Aug 13, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

Experience with beta blockers in heart failure mortality trials

E J Eichhorn1

  • 1University of Texas Southwestern Medical Center, Dallas 75216, USA.

Clinical Cardiology
|October 20, 1999
PubMed

Insights

Beta blockers significantly reduce mortality in chronic heart failure patients by improving cardiac function and quality of life, offering survival benefits beyond ACE inhibitors.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Chronic heart failure management involves inhibiting the renin-angiotensin-aldosterone and sympathetic nervous systems.
  • Angiotensin-converting enzyme (ACE) inhibitors show modest mortality reductions but do not fully address sympathetic overactivity.
  • Beta blockers represent a crucial therapeutic class for heart failure with demonstrated survival benefits.

Purpose of the Study:

  • To review the efficacy of beta blockers in managing chronic heart failure.
  • To compare the impact of beta blockers versus ACE inhibitors on mortality and cardiac function.
  • To highlight the benefits of beta blockers, including improved ejection fraction and reduced mortality.

Main Methods:

  • Meta-analysis of clinical trials involving ACE inhibitors in heart failure.
  • Review of clinical trial data for beta blockers, including the US Carvedilol trial and MERIT-HF.
  • Analysis of outcomes such as mortality, left ventricular ejection fraction, and cardiac dimensions.

Main Results:

  • ACE inhibitors reduced mortality by 13-33%, but high mortality persists due to unaddressed sympathetic stimulation.
  • Beta blockers demonstrated significant reductions in all-cause mortality (US Carvedilol trial: 65%) and heart failure mortality (MERIT-HF: 49%).
  • Beta blockers improve left ventricular ejection fraction, reduce cardiac dimensions, and enhance quality of life.

Conclusions:

  • Beta blockers offer substantial survival benefits in chronic heart failure, surpassing the effects of ACE inhibitors alone.
  • The positive effects of beta blockers on mortality and cardiac function underscore their importance in heart failure therapy.
  • Ongoing trials will further elucidate potential differences between beta-blocker subclasses and their effects across diverse patient populations.

More Related Videos

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...